Based on these results, Novartis sponsored a clinical trial (NCT04097821) using the human P-selectin antibody Crizanlizumab, which was effective in reducing pain crises in patients with Sickle Cell Anemia [22] and MF. This evidence concerns the gene SELP and sickle cell disease.